Unlearn.AI Announces Results Generated from First-of-its-Kind Machine Learning Platform to Accelerate Alzheimer’s Drug Development


Technology creates Digital Twins and Intelligent Control Arms to reduce clinical trial timelines and improve confidence in trial results


‘Digital Twin’ Advances Poised to Expand Clinical Trial Reach

Michael Causey for ACRP

Digital twins enable faster recruitment with higher powered, individualized trials [capable of generating] additional data from the same or fewer number of patients.


The FDA needs to set standards for using artificial intelligence in drug development

Charles Fisher for STAT News

Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.


Broadening Role for External Control Arms in Clinical Trials

Karen Tkach Tuzman for BioCentury

How Companies Are Populating External Control Arms To Speed Clinical Trial Enrollment